Cardiff Oncology, Inc. (CRDF)
Market Cap | 79.97M |
Revenue (ttm) | 391,000 |
Net Income (ttm) | -39.47M |
Shares Out | 44.68M |
EPS (ttm) | -0.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,340 |
Open | 1.78 |
Previous Close | 1.79 |
Day's Range | 1.76 - 1.79 |
52-Week Range | 1.13 - 3.56 |
Beta | 1.60 |
Analysts | Buy |
Price Target | 8.16 (+363.64%) |
Earnings Date | Feb 23, 2023 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for met... [Read more]
Financial Performance
In 2021, CRDF's revenue was $359,000, a decrease of -1.91% compared to the previous year's $366,000. Losses were -$28.32 million, 25.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 363.64% from the latest price.
News

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

Cardiff Oncology to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

Cardiff Oncology to Present at the Jefferies London Healthcare Conference
SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12 th announcement, show durable responses to treatment and support initiation of ONSEMBLE, a randomized P...

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expe...

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC...

Cardiff Oncology to Present at Upcoming Investor Conferences in September
SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
Event to feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs Event to take place at 4:30 PM ET...

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival benefit compared to treatment with either a...

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
SAN DIEGO , July 5, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, t...

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median progression-free survival that substantially exceed ...

Cardiff Oncology Announces Departure of Chief Medical Officer
SAN DIEGO , April 12, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers...

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA Dise...

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models
- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer mode...

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...